- Influenza vaccination was safe and effective during trastuzumab treatment in patients with HER2+ breast cancer participating in a nonrandomized Swedish trial.
Why this matters
- Patients with cancer are at increased risk for infection because of immunosuppression caused by underlying malignancy or its treatment.
- This trial provides empirical support for the current recommendation to offer influenza vaccination to patients with breast cancer being treated with targeted therapy.
- Nonrandomized, open-label, multicenter trial of trivalent influenza vaccine administered to 20 patients with nonmetastatic breast cancer during trastuzumab treatment (midcycle) and 37 healthy control participants.
- The vaccine contained inactivated A/California/7/2009 (H1N1) pdm09, A/Hongkong4801/2014 (H3N2), and B/Brisbane/60/2008.
- Seroprotection rate was defined as at least 1:40 geometric mean titers of hemagglutination inhibition for H1N1 and influenza B strain.
- Funding: Uppsala‐Örebro Regional Research Council.
- No difference in seroprotection rate between patients with breast cancer and control participants for:
- H1N1: 100% in both groups.
- Influenza B strain: 78.9% vs 89.2% (P=.423).
- Both groups had an increase in geometric mean titers compared with baseline, and the increase was apparent at both 4 and 12 weeks after vaccination.
- Adverse events were uncommon and mild in the breast cancer group; 1 serious adverse event unrelated to vaccination occurred.
- Nonrandomized, open-label design.
- Small sample size.